Xvivo Perfusion Aktiebolag

Financial Performance

• Net sales amounted to SEK 241.0 million, representing 10 percent growth in SEK and 23 percent organic growth in local currencies.
• Operating income before depreciation and amortization (EBITDA) was SEK 51.1 million, corresponding to a 21 percent margin.

| Nyckeltal | 2025 | 2024 | | :--- | :--- | :--- | | Nettomsättning, MSEK | 812 | 822 | | Bruttomarginal, % | 74 | 75 | | EBIT (Rörelsemarginal), % | 11 | 11 | | EBIT (Rörelsemarginal) (justerad), % | 11 | 14 | | EBITDA, % | 21 | 20 | | EBITDA (justerad), % | 20 | 22 | | Nettomarginal, % | 3 | 21 | | Soliditet, % | 89 | 90 | | Resultat per aktie, SEK | 0,80 | 5,47 | | Eget…